A study on drug utilization pattern of antiplatelet and anticoagulant drugs in the medicine department of a tertiary care teaching hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20261961Keywords:
Antiplatelet drugs, Anticoagulants, Drug utilization review, Cardiovascular diseases, Prescribing patterns, Adverse drug reactionsAbstract
Background: Antiplatelet and anticoagulant therapies are essential in the prevention and management of thromboembolic disorders, particularly cardiovascular and cerebrovascular diseases. Evaluation of prescribing patterns is necessary to ensure rational drug use and minimize adverse events. This study assessed the utilization patterns, prescribing appropriateness, drug interactions, adverse drug reactions and treatment outcomes of antiplatelet and anticoagulant therapy.
Methods: A six-month prospective observational study (November 2024 to April 2025) was conducted in the medicine ward, Coronary care unit, and Medicine intensive care unit of a tertiary care teaching hospital in Tamil Nadu. Data from 100 patients receiving antiplatelet and anticoagulant therapy were collected using a structured proforma and analyzed using JASP software.
Results: Most patients were aged 51-70 years and were predominantly male. Hypertension (61%) and diabetes mellitus (47%) were the most common comorbidities, while coronary artery disease was the leading indication for therapy. Aspirin (93%), clopidogrel (74%) and heparin (47%) were the most frequently prescribed drugs. Dual antiplatelet therapy was commonly utilized and 41% of patients received combination therapy. Seventeen potential drug interactions and five adverse drug reactions were identified. Significant differences in treatment outcomes were observed among drug groups (p<0.05). Ninety percent of prescribed drugs were in accordance with standard treatment guidelines.
Conclusions: Antiplatelet and anticoagulant therapies were widely used for thromboembolic disorders, with prescribing practices largely consistent with treatment guidelines and favorable treatment outcomes. However, polypharmacy, potential drug interactions and adverse drug reactions highlight the need for continuous prescription monitoring and individualized patient care.
References
WHO. Introduction to drug utilization research. 2003. Available at: https://apps.who.int/iris/handle/10665/42627. Accessed on 30 March 2026.
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Manual of Medicine. 18th ed. New York: McGraw-Hill Education. 2012.
Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. JAMA. 2014;311(11):1150-9.
Lloyd-Jones DM, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American heart association. Circulation. 2010;121(7):e46-215.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-32.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47.
Kakkar AK, Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Bounameaux H, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-94.
Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835-46.
WHO. WHO model prescribing information: drugs used in skin diseases: aspirin. 2019. Available at: https://www.who.int/publications/i/item/aspirin-pm-en . Accessed on 30 March 2026.
Katzung BG, Vanderah TW, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education. 2021.
Sanofi-Aventis U.S. LLC. Clopidogrel bisulfate tablets: prescribing information. 2022. Available at: https://www.accessdata.fda.gov. Accessed on 30 March 2026.
Goodman LS, Gilman AG. The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education. 2018.
Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Chest. 2001;119(1):64S-94.
Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688-98.
Guyatt GH, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.
Northwind Pharmaceuticals LLC. Warfarin sodium: highlights of prescribing information. 2015. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9d8fb69-a4c7-48cb-a4a9-e5d18eb4fd63 . Accessed on 30 March 2026.
Reddy PR, Prathul P, Jayalakshmi A, Anusha SB, Raj VCR. Drug utilization evaluation of antiplatelet agents in a tertiary care teaching hospital: a prospective observational study. Int J Pharm Drug Anal. 2021;9(3):218-29.
Vyas S, Dagar W, Dhanawat M, Manzoor S, Gupta S, Das R, et al. Drug utilization analysis of anticoagulant and antiplatelet drugs in cardiology department of a tertiary care hospital. J Young Pharm. 2022;14(1):122-5.
Raouf S, Namdarifar F, Malekpour Shahraki E, Murthy S. A study of using anticoagulants in a tertiary care hospital in Bangalore: a prospective study. Health Sci Surveill Syst. 2021;9(4):286-90.
Singh V, Gopinath K, Behzadpour A, Meera NK. Anticoagulant utilization evaluation in a tertiary care teaching hospital: an observational prospective study in medical inpatients. Indian J Pharm Pract. 2015;8(2):61-6.
Downloads
Published
How to Cite
Issue
Section
